Phong Phu Pharmaceutical JSC (HNX: PPP)
Vietnam
· Delayed Price · Currency is VND 16,600
-100 (-0.60%)
At close: Jan 24, 2025
HNX:PPP Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 137,548 | 152,172 | 150,575 | 133,289 | 116,257 | Upgrade
|
| Revenue Growth (YoY) | -9.61% | 1.06% | 12.97% | 14.65% | -23.28% | Upgrade
|
| Cost of Revenue | 91,175 | 103,002 | 99,285 | 88,053 | 80,245 | Upgrade
|
| Gross Profit | 46,373 | 49,170 | 51,290 | 45,237 | 36,012 | Upgrade
|
| Selling, General & Admin | 26,149 | 26,037 | 26,096 | 25,543 | 23,330 | Upgrade
|
| Operating Expenses | 26,149 | 26,037 | 26,096 | 25,543 | 23,330 | Upgrade
|
| Operating Income | 20,224 | 23,133 | 25,194 | 19,693 | 12,682 | Upgrade
|
| Interest Expense | - | - | -45.36 | -434.42 | -1,649 | Upgrade
|
| Interest & Investment Income | 1,391 | 1,327 | 561.01 | 109.53 | 187.27 | Upgrade
|
| Other Non Operating Income (Expenses) | 195.27 | 106.8 | 93.21 | 77.97 | 332.1 | Upgrade
|
| EBT Excluding Unusual Items | 21,810 | 24,567 | 25,802 | 19,446 | 11,552 | Upgrade
|
| Pretax Income | 21,810 | 24,567 | 25,802 | 19,446 | 11,552 | Upgrade
|
| Income Tax Expense | 4,451 | 4,447 | 5,191 | 2,553 | 1,737 | Upgrade
|
| Net Income | 17,359 | 20,120 | 20,611 | 16,893 | 9,815 | Upgrade
|
| Net Income to Common | 17,359 | 20,120 | 20,611 | 16,893 | 9,815 | Upgrade
|
| Net Income Growth | -13.72% | -2.38% | 22.01% | 72.11% | -19.63% | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | 0.79% | -0.07% | -0.34% | -0.72% | 5.58% | Upgrade
|
| EPS (Basic) | 1766.00 | 2063.00 | 2112.00 | 1725.00 | 995.00 | Upgrade
|
| EPS (Diluted) | 1766.00 | 2063.00 | 2112.00 | 1725.00 | 995.00 | Upgrade
|
| EPS Growth | -14.40% | -2.32% | 22.43% | 73.37% | -23.87% | Upgrade
|
| Free Cash Flow | 16,787 | 17,428 | 20,117 | 18,129 | 9,045 | Upgrade
|
| Free Cash Flow Per Share | 1707.78 | 1786.98 | 2061.38 | 1851.27 | 916.90 | Upgrade
|
| Dividend Per Share | - | - | 1400.000 | - | - | Upgrade
|
| Gross Margin | 33.71% | 32.31% | 34.06% | 33.94% | 30.98% | Upgrade
|
| Operating Margin | 14.70% | 15.20% | 16.73% | 14.77% | 10.91% | Upgrade
|
| Profit Margin | 12.62% | 13.22% | 13.69% | 12.67% | 8.44% | Upgrade
|
| Free Cash Flow Margin | 12.20% | 11.45% | 13.36% | 13.60% | 7.78% | Upgrade
|
| EBITDA | 24,437 | 27,949 | 31,419 | 25,871 | 18,878 | Upgrade
|
| EBITDA Margin | 17.77% | 18.37% | 20.87% | 19.41% | 16.24% | Upgrade
|
| D&A For EBITDA | 4,213 | 4,816 | 6,225 | 6,178 | 6,196 | Upgrade
|
| EBIT | 20,224 | 23,133 | 25,194 | 19,693 | 12,682 | Upgrade
|
| EBIT Margin | 14.70% | 15.20% | 16.73% | 14.77% | 10.91% | Upgrade
|
| Effective Tax Rate | 20.41% | 18.10% | 20.12% | 13.13% | 15.03% | Upgrade
|
| Revenue as Reported | 137,348 | 152,172 | 150,575 | 133,289 | 116,257 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.